Dedrone Launches Low Collateral Counter-Drone Jammer for Urban Environments
New solution joins Dedrone’s successful DroneDefender Jammer, which has sold over 700 precision jammers for…
Month: October 2022
William Blair Continues Investment Banking Growth in Europe with New Tech Managing Director
CHICAGO & LONDON–(BUSINESS WIRE)–William Blair, the premier global boutique with expertise in investment banking, investment…
Freelance Payroll Solution Solar Staff Launches in the USA
The company provides U.S. businesses with an opportunity to pay freelancers from emerging markets like…
Axiom Exhibiting at Outsourcing in Clinical Trials New England 2022
TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) — Axiom Real-Time Metrics (“Axiom”), a premier provider of…
Loos, France, Isovital Headquarter, Oct 12th 2022 – Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDER
Loos, France, Isovital Headquarter, Oct 12th 2022 – Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW…
Codex DNA Announces Plan to Change Corporate Name to Telesis Bio
Novel name reflects expansion of capabilities and solutions SAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE)…
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel, Oct. 12, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty…
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
Company expects to commence patient enrollment and dosing in Q1 2023 OCALA, Fla, Oct. 12,…
Junshi Biosciences and Coherus Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology
Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared…
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader…
Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease…
T2 Biosystems Announces Reverse Stock Split Effective Today
TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2022…
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
Six abstracts selected for presentation, including three oral presentations WALTHAM, Mass., Oct. 12, 2022 (GLOBE…
Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting
– Three late-breaking presentations to feature emerging evidence of VRDN-001 efficacy and differentiation – –…
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell…
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs
Accomplished industry leader with over twenty years of experience building lasting relationships with global regulatory…
Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium
Initial Phase 1/1b patient data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced…
Synthetic Biologics Rebrands as Theriva Biologics
Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV)…
Amolyt Pharma Announces Positive Safety and Efficacy Results from Second Patient Cohort in its Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism
93% of patients in Cohort 2 discontinued both active vitamin D and oral calcium supplementation,…